Study of BHV-1400 in IgA Nephropathy

Recruiting now · Phase 1

Conditions studied: IgA Nephropathy

In brief

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Key facts

Study ID

NCT07054684

Run by

Biohaven Therapeutics Ltd.

People needed

20

Starts

2025-07-30

Expected to finish

2027-07-01

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Site-001 — Farmington, Connecticut, United States (enrolling)
• Site-003 — Miami Lakes, Florida, United States (enrolling)
• Site-011 — Miami Lakes, Florida, United States (enrolling)
• Site-013 — Orlando, Florida, United States (enrolling)
• Site-005 — Pembroke Pines, Florida, United States (enrolling)
• Site-008 — Lawrenceville, Georgia, United States (enrolling)
• Site-009 — Hinsdale, Illinois, United States (enrolling)
• Site-012 — Indianapolis, Indiana, United States (enrolling)
• Site-015 — Shelby, Michigan, United States (enrolling)
• Site-006 — Chesterfield, Missouri, United States (enrolling)
• Site-002 — Dakota Dunes, South Dakota, United States (enrolling)
• Site-014 — Houston, Texas, United States (enrolling)
• Site-004 — Houston, Texas, United States (enrolling)
• Site-016 — Salt Lake City, Utah, United States (enrolling)
• Site-007 — Leicester, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.